Financial relationships in economic analyses of targeted therapies in oncology

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1316-1320

  Valachis, Antonis ^a   Polyzos, Nikolaos P ^c   Nearchou, Andreas ^a   Lind, Pehr ^a,b   Mauri, Davide ^d  

^a Mälarjukhuset ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d General Hospital of Lamia   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; FINANCIAL MANAGEMENT; FUNDING; HUMAN; MEDLINE; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONFLICT OF INTEREST; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; ECONOMICS; FACTUAL DATABASE; FEMALE; MALE; NEOPLASM; PUBLISHING; QUALITATIVE RESEARCH; REVIEW; SWEDEN; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASMS; PUBLICATION BIAS; QUALITATIVE RESEARCH; SWEDEN; UNITED STATES;

EID: 84861757517     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.6078     Document Type: Article

References (25)

1. Soria JC, Blay JY, Spano JP, et al: Added value of molecular targeted agents in oncology. Ann Oncol 22:1703-1716, 2011
2. Yin W, Jiang Y, Shen Z, et al: Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: At meta-analysis of published randomized controlled rials. PLoS One 6:e21030, 2011
3. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
4. Zambrowski JJ: Cost of cancer in France: Pharmaceutical expenditure as part of global patients'care. Bull Cancer 95:535-541, 2008
5. Bell CM, Urbach DR, Ray JG, et al: Bias in published cost effectiveness studies: Systematic review. BMJ 332:699-703, 2006
6. Friedberg M, Saffran B, Stinson TJ: Evaluation of conflict of interest in economic analysis of new drugs used in oncology. JAMA 282:1453-1457, 1999 (Pubitemid 29493799)
7. Hartmann M, Knoth H, Schulz D, et al: Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 89:1405-1408, 2003 (Pubitemid 37386591)
8. Jang S, Chae YK, Haddad T, et al: Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: A systematic review. Breast Cancer Res Treat 121:273-279, 2010
9. Baker CB, Johnsrud MT, Crismon ML, et al: Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 183:498-506, 2003 (Pubitemid 37533195)
10. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326:1167-1170, 2003 (Pubitemid 36649048)
11. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
12. Winter MC, Hancock BW: Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223-235, 2009
13. Demetri GD, Benjamin RS, Blanke CD, et al: NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)-Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5:S1-S29, 2007
14. European Medicines Agency: Questions and answers on the review of Avastin (bevacizumab) in the treatment of metastatic breast cancer. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2010/12/ WC500099939.pdf
15. Kane RC, Farrell AT, Saber H, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278, 2006 (Pubitemid 46095398)
16. Center for Drug Evaluation and Research: Application number 22-334: Summary review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022334s000-SumR.pdf
17. Shih YC, Chien CR, Xu Y, et al: Economic burden of renal cell carcinoma in the US: Part II. An updated analysis. Pharmacoeconomics 29:331-341, 2011
18. Gianni L, Pienkowski T, Im Y-H, et al: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase ii study ('Neo-Sphere'). Cancer Res 70, 2010 (suppl; abstr nr S3-2)
19. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
20. Hopewell S, Loudon K, Clarke MJ, et al: Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 21:MR000006, 2009
21. Polyzos NP, Valachis A, Mauri D, et al: Industry involvement and baseline assumptions of costeffectiveness analyses: Diagnostic accuracy of the Papanicolaou test. CMAJ 183:E337-E343, 2011
22. Knox KS, Adams JR, Djulbegovic B, et al: Reporting and dissemination of industry versus nonprofit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol 11:1591-1595, 2000 (Pubitemid 32104759)
23. Eichler HG, Kong SX, Gerth WC, et al: Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 7:518-528, 2004 (Pubitemid 39390832)
24. Russell LB, Gold MR, Siegel JE, et al: The role of cost-effectiveness analysis in Health and Medicine. JAMA 276:1172-1177, 1996 (Pubitemid 26329746)
25. Tufts Medical Center: Cost-Effectiveness Analysis Registry. https://research.tufts-nemc.org/cear4/default.aspx